1.Treating Relapsed or Refractory B-cell Lymphomas (Posted: 07/22/2008) - Scientists are studying the drug flavopiridol in this early phase clinical trial to see if it can be effective in treating diffuse large B-cell lymphoma and mantle cell lymphoma that has relapsed or been resistant to treatment. 2.Batracylin for Patients with Advanced Solid Tumors or Lymphoma (Posted: 04/01/2008) - In this phase I trial, patients with solid tumors or lymphomas for which standard therapies do not exist or are of minimum benefit and who are slow acetylators, as determined by a blood test, will be treated with increasing doses of the drug batracylin. 3.New Targeted Therapy for Solid Tumors and Lymphomas (Posted: 08/10/2004, Updated: 07/18/2007) - In this trial, researchers are trying to determine whether a new chemotherapy agent called 17-DMAG will help prevent cancer cells from growing in patients with solid tumors or lymphomas. The agent inhibits a protein called HSP-90 that is found more often in cancer cells than in normal cells. 4.Targeted Therapy for Lymphoid Cancers (Posted: 05/29/2007) - Patients with T-cell or B-cell lymphoid cancers that have recurred or progressed despite prior chemotherapy will receive the drug ABT-263 orally for up to a year in this phase I/II clinical trial. 5.Monoclonal Antibody Therapy for Treatment-Resistant Blood Cancers (Posted: 03/29/2005, Updated: 05/16/2007) - This phase I dose-escalation study is investigating safety and tolerability of siplizumab, and will determine the maximum dose that can be given to patients with CD2-positive lymphoproliferative disease.
